- ►nih.gov - Free from Publisher Z Zhou, R Althin, BS Sforzolini, R Dhawan - British Journal of Ophthalmology, 2004 - bjo.bmj.com Methods: The UK General Practice Research Database was used to identify newly
diagnosed (after 1 January 1997) open angle glaucoma patients who were naive to
therapy with any of six index drug groups: carbonic anhydrase inhibitors, ... Cited by 14 - Related articles - BL Direct - All 10 versions
GA Alyahya, J Hietanen, S Heegaard, T … - Acta Ophthalmologica Scandinavica, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 5 - Related articles - All 2 versions
- ►mt.gov [PDF] G Reardon, GF Schwartz, E Mozaffari - American journal of ophthalmology, 2004 - Elsevier Patients were at least 20 years of age initiating therapy between July 1, 1996,
and June 30, 2002, with betaxolol, bimatoprost, brimonidine, dorzolamide,
latanoprost, timolol, or travoprost as monotherapy. Patients must have been ... Cited by 44 - Related articles - All 5 versions
- ►iovs.org SY Ghoghawala, MJ Mannis, CE Pullar, MI … - Investigative ophthalmology & visual science, 2008 - ARVO RESULTS. The β-AR agonist isoproterenol decreased AMCE cell migratory speed to
70% of untreated controls, and this was correlated with a 0.60-fold decrease in
levels of activated phospho-ERK (P-ERK). Treatment with the β-AR ... Cited by 2 - Related articles - BL Direct - All 3 versions
MN Lazaridou, DMI Montgomery, W Onn Ho, … - Current Medical Research and Opinion®, 2008 - informahealthcare.com Methods: The glaucoma database of the Glasgow Royal Infirmary was reviewed
retrospectively to identify patients ≥ 18 years of age with primary open-angle
glaucoma or ocular hypertension in at least one eye who had been switched ... Cited by 2 - Related articles - All 6 versions
J Wilensky, RG Fiscella, AM Carlson, LS … - American journal of ophthalmology, 2006 - Elsevier Glaucoma patients in the IMS Health LifeLink database with a pharmacy claim for
latanoprost (n = 1567), travoprost (n = 381), or bimatoprost (n = 476) between
September, 2001 and March, 2002 who had no claims for IOP-lowering ... Cited by 37 - Related articles - All 7 versions
- ►nih.gov [PDF] JD Stein, FA Sloan, PP Lee - American journal of ophthalmology, 2007 - Elsevier To determine rates of glaucoma medication utilization among glaucoma suspects in
the Medicare Current Beneficiary Survey (MCBS) and identify recent utilization
patterns for various hypotensive drug classes. Cited by 3 - Related articles - All 14 versions
JP Nordmann, A Lafuma, C Deschaseaux, G … - Journal of glaucoma, 2005 - journals.lww.com Skip Navigation Links Home > December 2005 - Volume 14 - Issue 6 > Clinical
Outcomes of Glaucoma Treatments Over a Patient Life... ... From *Hôpital des
Quinze-Vingts, Centre Hospitalier National d'Ophtalmologie, Paris, France; ... Cited by 13 - Related articles - BL Direct - All 3 versions
G Reardon, GF Schwartz, E Mozaffari - European journal of ophthalmology, 2003 - ncbi.nlm.nih.gov PURPOSE: To evaluate persistency with monotherapy in the treatment of glaucoma
in patients new to pharmacological management. METHODS: This population-based,
retrospective cohort study, using managed care administrative claims data, ... Cited by 22 - Related articles - BL Direct - All 3 versions
S Dasgupta, V Oates, BK Bookhart, B Vaziri, … - American Journal of Managed Care, 2002 - pfizer.se Glaucoma is the second leading cause of blindness worldwide.1 In the United
States alone, more than 15 million persons are reported to have glaucoma.2 The
underlying mecha- nisms for development of the progressive, Cited by 40 - Related articles - View as HTML - BL Direct - All 10 versions
